["{\n\"step_by_step_thinking\": \"The question is about a study conducted over 1 year to assess the antileukemic activity of a new tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis. The study assigns patients to successive dose cohorts, and treatment efficacy is determined based on regular complete blood counts and bone marrow assessments. This suggests that the study is an open-label clinical trial, where all participants receive the same treatment.\",\n\"answer_choice\": \"C\"\n}"]